US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LILLE, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SACLAY on Feb. 3 for "Use of materials made of cross-linked Beta-cyclodextrins for the treatment of tuberculosis" (French Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,539,312, issued on Feb. 3, was assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris), UNIVERSITE DE LILLE (Lille, France), INSTITUT PASTEUR DE LILLE (Lille, France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris) and UNIVERSITE PARIS-SACLAY (Paris).

"Use of materials made of cross-linked Beta-cyclodextrins for the treatment of tuberculosis" was invented by Priscille Brodin (Lille, France), Alain Boulard (Lille, France), Ruxandra Gref (Orsay, France) and Arnaud Machelart (Lille, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "Multi-drug resistant tuberculosis (TB) is a major public health problem concern...